Cargando…

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Habibi, Javad, Aroor, Annayya R., Sowers, James R., Jia, Guanghong, Hayden, Melvin R., Garro, Mona, Barron, Brady, Mayoux, Eric, Rector, R. Scott, Whaley-Connell, Adam, DeMarco, Vincent G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237274/
https://www.ncbi.nlm.nih.gov/pubmed/28086951
http://dx.doi.org/10.1186/s12933-016-0489-z
_version_ 1782495502193917952
author Habibi, Javad
Aroor, Annayya R.
Sowers, James R.
Jia, Guanghong
Hayden, Melvin R.
Garro, Mona
Barron, Brady
Mayoux, Eric
Rector, R. Scott
Whaley-Connell, Adam
DeMarco, Vincent G.
author_facet Habibi, Javad
Aroor, Annayya R.
Sowers, James R.
Jia, Guanghong
Hayden, Melvin R.
Garro, Mona
Barron, Brady
Mayoux, Eric
Rector, R. Scott
Whaley-Connell, Adam
DeMarco, Vincent G.
author_sort Habibi, Javad
collection PubMed
description Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium glucose transporter-2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empagliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall motion (>tissue Doppler derived E′/A′ ratio) and increased left ventricular (LV) filling pressure (<E/E′ ratio). Although these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-016-0489-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5237274
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52372742017-01-18 Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes Habibi, Javad Aroor, Annayya R. Sowers, James R. Jia, Guanghong Hayden, Melvin R. Garro, Mona Barron, Brady Mayoux, Eric Rector, R. Scott Whaley-Connell, Adam DeMarco, Vincent G. Cardiovasc Diabetol Original Investigation Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium glucose transporter-2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empagliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall motion (>tissue Doppler derived E′/A′ ratio) and increased left ventricular (LV) filling pressure (<E/E′ ratio). Although these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-016-0489-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-13 /pmc/articles/PMC5237274/ /pubmed/28086951 http://dx.doi.org/10.1186/s12933-016-0489-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Habibi, Javad
Aroor, Annayya R.
Sowers, James R.
Jia, Guanghong
Hayden, Melvin R.
Garro, Mona
Barron, Brady
Mayoux, Eric
Rector, R. Scott
Whaley-Connell, Adam
DeMarco, Vincent G.
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title_full Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title_fullStr Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title_full_unstemmed Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title_short Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
title_sort sodium glucose transporter 2 (sglt2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237274/
https://www.ncbi.nlm.nih.gov/pubmed/28086951
http://dx.doi.org/10.1186/s12933-016-0489-z
work_keys_str_mv AT habibijavad sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT aroorannayyar sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT sowersjamesr sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT jiaguanghong sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT haydenmelvinr sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT garromona sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT barronbrady sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT mayouxeric sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT rectorrscott sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT whaleyconnelladam sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes
AT demarcovincentg sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes